TOHKnet and Adtran conduct Japan’s first 50G PON trial on a live network

Adtran today announced that TOHKnet has completed Japan’s first live network trial demonstrating the coexistence of 50G PON, XGS-PON and EPON on a single fiber. Conducted in Sendai using Adtran’s SDX 6400 Series OLT, the demo showed how the platform enables three generations of PON technology to operate together in a live service environment. The results highlight a realistic path for operators to introduce 50G PON capacity while maintaining continuity for existing services, maximizing the...
Anglais

Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board

Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds...
Anglais

LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care

LabPMM®, an Invivoscribe®subsidiary, today announced the global availability of its newKMT2Ameasurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing...
Anglais

4Moving Biotech Completes Enrollment in Phase 2a INFLAM MOTION Study Evaluating First-in-class Intra-articular GLP-1 Therapy Targeting Synovitis as a Driver of Pain and Disease Progression in Knee Osteoarthritis

4Moving Biotech (4MB), a clinical-stage biotechnology company dedicated to developing first-in-class therapies for inflammatory knee osteoarthritis, today announced the completion of patient enrollment in INFLAM MOTION, its international Phase 2a proof-of-concept study. The trial is evaluating the efficacy and safety of 4P004, an investigational intra-articular GLP-1 receptor agonist designed to address the...
Anglais

Kioxia Announces KIOXIA GP1 Series Super High IOPS SSDs for AI Applications

Kioxia Corporation today announced the KIOXIA GP1 Series PCIe®6.0 NVMe™ SSDs, the first product in its KIOXIA GP Series of Super High IOPS SSDs optimized for GPU direct access. Building on the KIOXIA GP Series technology introduced earlier this year1, the KIOXIA GP1 Series delivers up to 10 million random read IOPS2using KIOXIA XL-FLASH™ generation 2 flash memory, enabling flash-based memory extension to help address the growing performance and memory demands of AI infrastructure. Evaluation samples will be available to select customers by the end of 20263. The KIOXIA GP1 Series will...
Anglais
Subscribe to The Agency